Group 1 - The core viewpoint of the article highlights that Rui Feng Hui Bang, a well-known private equity firm, has conducted research on a listed company, Weili Medical, focusing on its strategies to address domestic medical consumables procurement and the growing demand for overseas production capacity [1] - Weili Medical is actively establishing a factory in Mexico starting in 2024 to meet production needs and is also preparing a second overseas production base in Indonesia, which is expected to complete its first phase of construction and production by the end of this year [1] - The company is developing key products in its anesthesia line, nursing line, and urology field, aiming to launch these products quickly to better meet clinical needs while expanding its product range through technology transformation [1]